Prognostic Implication of LDL-C Variability and Its Association with Lipid-Lowering Strategies: Insights from the RACING and LODESTAR Trials Article Swipe
Related Concepts
Jaeoh Lee
,
Sripal Bangalore
,
Kyeong Ho Yun
,
Sang‐Hyup Lee
,
Yong‐Joon Lee
,
Seung‐Jun Lee
,
Sung‐Jin Hong
,
Chul‐Min Ahn
,
Jung‐Sun Kim
,
Byeong‐Keuk Kim
,
Young‐Guk Ko
,
Donghoon Choi
,
Yangsoo Jang
,
Bum‐Kee Hong
,
Myeong‐Ki Hong
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3349/ymj.2024.0476
· OA: W4411076171
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3349/ymj.2024.0476
· OA: W4411076171
Compared to high-intensity statin therapy, LDL-C variability was not increased with the moderate-intensity statin plus ezetimibe combination therapy; however, it was increased in the treat-to-target strategy. Even among those treated with moderate- or high-intensity statins or statins with a target LDL-C levels of 50-70 mg/dL, increased LDL-C variability was associated with higher risk of adverse cardiovascular outcomes.
Related Topics
Finding more related topics…